Abstract Increased telomerase activity can be blocked by targeting the hTERT activity at both RNA and catalytic subunits. Various inhibitors had been used to regulate hTERT activity in glioblastoma cell lines and showed promising results. The present study hypothesized that the telomerase specific inhibitor BIBR1532 can effectively down-regulate the telomerase activity in LN18 glioblastoma cell line. LN18 glioblastoma cell line was treated with various concentrations of BIBR1532 at different time intervals. MTT assay was performed to determine cell viability after BIBR1532 treatment. hTERT mRNA and protein expression were determined by qRT-PCR and western blotting, respectively. Flow cytometry and TRAP assay was performed to detect the rate of apoptosis and telomerase activity in treated and control samples. One-way ANOVA was performed to compare the mean values of variables in control and BIBR1532 treated groups. LN18 cells showed a significant dose dependent cytotoxic effect after treatment with BIBR1532. hTERT mRNA expression in cells treated with 25, 100 and 200 lM BIBR1532 treated groups was decreased * 21, * 61.2, and * 77%, respectively (p \ 0.05). We also observed that, BIBR1532 treatment reduced the expression of hTERT protein in LN18 cells in a dose dependent manner. The Flow cytometry data showed that, the drug induced significant increase in the total percentage of apoptotic cells with 200 lM concentration of BIBR1532 at all time points. BIBR1532 exhibited potent inhibition of telomerase activity in a dosedependent manner in LN18 cells. BIBR1532 could induce apoptosis in LN18 cells through the downregulation of telomerase activity at transcriptional and translational level. We conclude that BIBR1532 may be a therapeutic agent to suppress telomerase activity, however, further efforts are necessary in order to explore this therapeutic strategy.
Introduction
Gliomas are the most common heterogeneous primary brain tumors which arise from glial cells. In 2007, World Health Organization (WHO) classified gliomas into four different grades based on the cell type and severity (Louis et al. 2007 ). Among these glioblastoma (GB) is the most frequent and aggressive brain tumor in adults (Arvold and Reardon 2014) . The hallmark features of GB are uncontrolled cellular proliferation, invasion, ability to form new blood vessels and evasion of apoptosis (Furnari et al. 2007) . Even with the advancement in the field of surgery, chemotherapy and radiotherapy the prognosis of GB patients remains poor due to the presence of cancer stem cells that makes these tumors resistant to chemo and radio therapy (Singh et al. 2003; Yuan et al. 2004) . Numerous molecular and genetic alterations which maintain molecular phenotypes of tumors are frequently seen in gliomas (Sathornsumetee et al. 2007; Zhang et al. 2012) .
Human telomeres are unique protein-DNA complexes present at the ends of all eukaryotic chromosomes with a tandem repeats of TTAGGG sequences. They protect the chromosomes from end to end fusions and maintain genomic stability (Cong et al. 2002) . Telomeres also play a major role in aging and cancer (Blasco 2005) . Telomerase is a specialized ribonucleoprotein reverse transcriptase which maintains the telomeric TTAGGG repeats by adding DNA sequence repeats to the 3 0 end of chromosomes (Cong et al. 2002; Osterhage and Friedman 2009) . Telomerase holoenzyme consists of two major components: a catalytic protein component human telomerase reverse transcriptase (hTERT) and a RNA component (hTR) that acts as a template for adding hexanucleotide repeats (Artandi and DePinho 2010; Wai 2004) . The expression and activity of telomerase has been observed in 80-90% of all cancer cells and involves in increased cell proliferation, cellular immortality and tumorigenesis (Kong et al. 2015) . In contrast to that in most normal human cells the hTERT expression and telomerase activity are low or repressed (Counter et al. 1992; Harley et al. 1990 ). Hence the difference in hTERT expression and telomerase activity in cancer cells versus normal cells makes telomerase as an attractive target for the development of new cancer therapeutics. The expression and activity of telomerase correlated with the progression of malignant glioma (Falchetti et al. 1999; Komata et al. 2002) . Therefore, telomerase is an essential target for improving the prognosis and treatment of gliomas.
In the recent years several therapeutic approaches have been evaluated to inhibit telomerase activity and block cancer cell growth. Previous studies demonstrated that inhibition of hTERT by RNA interference and pharmacological agents reduces telomerase activity and allows cells to undergo apoptosis (Lavanya et al. 2016; Lu et al. 2012; Mergny et al. 2002) . In addition to that numerous telomerase inhibitors that block either the activity of the enzyme or recruitment of telomerase to telomeres have been developed. They are nucleoside analogs, catalytic inhibitors, hTR antisense oligonucleotides, ribozymes and G-quadruplex Ligands (Seimiya et al. 2002) . Inhibitors such as imetelstat (GRN163L) have demonstrated a promising pharmacokinetic profile with fewer side effects and are currently in phase I and II clinical trials (Asai et al. 2003; Marian et al. 2010 ).
2-[(E)-3-naphtalen-2-yl-but-2-enoylamino]-benzoic acid BIBR1532, one of the most potent and specific inhibitors of hTERT, has been discovered recently (Damm et al. 2001; Kong et al. 2015) . BIBR1532 is a nonpeptidic, non-nucleoside small molecule inhibitor that inhibits telomerase activity by specifically binding to the active site of hTERT (Damm et al. 2001) . It has been observed that BIBR1532 has a strong ability to reduce growth across various cancer cells including breast, leukemia, lung, ovarian, chondrosarcoma and germ cell tumors (Bashash et al. 2013; Damm et al. 2001; Meng et al. 2012; Mueller et al. 2007; Parsch et al. 2008; Ruden and Puri 2013) . In the present study we aim to investigate the effect of knockdown of hTERT and inhibition of telomerase activity by BIBR1532 in glioblastoma cells.
Materials and methods

Cell culture
The human glioblastoma cell line LN18 was purchased from the National Center for Cell Science (NCCS) (Pune, India). Cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) (Sigma Aldrich, St. Louis, MO, USA) containing 10% fetal bovine serum (Invitrogen, Life Technologies, Carlsbad, CA, USA) and antibiotics 100 U/ml penicillin and 100 lg/ml streptomycin (Life Technologies) at 37°C in a humidified atmosphere with 5% CO 2 and 95% air. The cells were grown in 6 well tissue culture plates and replated every 2-3 days to ensure log-phase growth. CHME-3, an immortalized human microglial cell line (Nijaguna et al. 2015 ) was a kind gift from Assistant Professor Manjunatha M Venkataswamy (Department of Neurovirology, NIMHANS, Bangalore). CHME3 cells were grown in Dulbecco's Modified Eagle's Medium (DMEM, Invitrogen) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, and 100 lg/ml penicillin-streptomycin (Invitrogen).
Drug treatment
The telomerase inhibitor BIBR1532 was obtained from (Genetix Biotech Asia Pvt Ltd., Bangalore, India). A stock solution of BIBR1532 at a concentration of 1 mM was prepared by dissolving the compound in sterile dimethylsulfoxide (DMSO), divided into aliquots and stored at -20°C until use. LN18 cells were treated with relative amounts of BIBR1532 stock solution to attain concentrations of 25, 50, 100 and 200 lM.
MTT assay
The inhibitory effect of BIBR1532 on the metabolic activity of LN-18 cells was assessed by the uptake of thiazolyl blue tetrazolium bromide (Sigma Aldrich) by viable cells. Briefly, LN-18 cells were seeded at 5000/well in 96-well culture plates and incubated with desired concentrations of BIBR1532 for 24, 48 and 72 h. After removing the media, cells were further incubated with MTT solution [5 mg/ml in phosphate buffered saline (PBS)] at 37°C for 2 h and the untreated cells were defined as the control group. The MTT reaction was terminated through the addition of 100 ll of DMSO. The results were read by measuring absorption at 570 nm (620 nm as a reference) using plate reader (Tecan, infinite M200 Pro, A-5082, Austria). The effect of BIBR1532 was calculated as a percentage of control cell growth. Each experiment was performed in triplicate and repeated three times to assess for consistency of results. CHME3 cells were also incubated with different concentrations of BIBR1532 and cell viability was measured after 24 and 48 h.
RNA isolation and quantification
Total cellular RNA from LN18 cells was isolated at 48 h after treatment with BIBR1532 using a Pure LinkTM RNA Mini Kit (Ambion, Life technologies) according to the manufacturer's instructions. The quantity of RNA samples was assessed spectrophotometrically using Nanodrop ND 2000c (Thermo Fisher Scientific, Waltham, MA, USA). RNA samples with a purity of 1.95-2.05 (A260/280) were used in this study. RNA stability was checked by formaldehyde agarose gel electrophoresis.
Quantitative real-time PCR One microgram of total RNA was reverse transcribed into cDNA using MMLV reverse-transcriptase, oligodT, dNTPs and buffer, following the manufacturer's instructions (Life Technologies). Power SYBR green universal master mix and 7500 fast real-time PCR system (Applied Biosystems, Foster City, CA, USA) were used for real-time PCR work. The details of primers are given in Table 1 . Thermal cycling conditions including an initial activation step at 95°C for 10 min, followed by 40 cycles, then each cycle at 95°C for 30 s, 53°C for 30 s, 72°C for 30 s and a final extension step at 72°C for 7 min. Each sample was assayed in triplicates. A housekeeping control gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control to correct for differences in the amount of RNA in each sample. Melt curve analysis was performed to confirm the specificity of the products, and the values for relative quantification were calculated based on the 2 (-DD CT) relative expression formula.
Western blotting
After treatment with BIBR1532, the LN-18 cells were harvested and lysed with cold RIPA lysis buffer [50 mM Tris, 150 mMNaCl, 1 mmol/l EDTA, 0.1% sodium dodecyl sulphate, 1% Triton X-100, 1 mol/l phenyl methyl sulfonyl fluoride (pH 8.0): SRL Ltd, Bangalore, India]. The lysate was centrifuged at 80009g for 20 min at 4°C. The protein content in the lysates was measured using Bradford assay (BioRad Laboratories Inc., Hercules, CA, USA). For western blot analysis 50 lg protein was resolved in 12% SDS-PAGE gels, transferred onto PVDF membranes (Bio-Rad) and subsequently incubated in blocking buffer (5% BSA, 1% Tween 20 in 20 mol/l Tris-buffered saline (pH 7.6); SRL Ltd) for 2 h. The membranes were incubated with monoclonal antihTERT antibody (#sc-377511; 1:1000) and antimouse secondary antibody conjugated to horseradish peroxidase (#sc-358914; 1:5000) for 1 h. The protein was detected with an enhanced chemiluminiscence detection kit (Bio-Rad Laboratories Inc.). Equal loading of protein was confirmed by stripping the blots and re-probing with monoclonal mouse antihuman b-tubulin (#sc-58882; 1:2000) antibody. Monoclonal antibodies were purchased from Santa Cruz Biotech Inc (Santa Cruz, Dallas, TX, USA). The bands were analyzed by NIH Image-J software (National Institutes of Health, Bethesda, MD, USA).
Flowcytometry
Flow cytometry assay was performed by Annexin V/PI double staining method (BD Pharmingen, San Diego, CA, USA) to evaluate the induction of apoptosis. LN-18 cells (2 9 10 5 ) were seeded in 6-well plates. The cells were treated with various concentrations of BIBR1532. The cells were harvested at different time points using trypsin, washed with 1X PBS and suspended in 100 ll of 1X binding buffer. The cells were incubated with 5 ll of fluorochrome-conjugated Annexin V and 5 ll of propidium iodide at room temperature in the dark for 15 min. Diverse labeling patterns allowed us to identify different cell populations: early apoptotic cells (PI-/Annexin V?); apoptosis/necrotic cells (PI?/Annexin V?) and viable cells (PI-/Annexin V-). The data were acquired by flow cytometry FACS Aria III (BD Biosciences). Apoptotic cells were detected and expressed as the percentage of total cells. The experiments were repeated three times.
Telomeric repeat amplification protocol (TRAP) assay
To investigate whether BIBR1532 treatment reduces telomerase activation, the enzymatic activity was measured by Telo TAGGG telomerase PCR ELISA kit (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer's protocol. In brief, LN18 cells were collected 48 h after treatment with BIBR1532 at various concentrations. The cells were washed with cold PBS, lysed in 200 ll lysis buffer and incubated on ice for 30 min. The lysate was centrifuged at 16,0009g at 4°C for 20 min. Later the supernatant was collected and the protein extracts were subjected to TRAP assay. For the TRAP reaction, 25 ll of reaction mixture, 10 lg of sample, and nuclease free water to make a final volume of 50 ll. PCR was performed and ELISA was carried out following the manufacturer's guidelines. A total of 5 ll of PCR products was added to a streptavidincoated 96-well plate and hybridized to a digoxigenin (DIG)-labeled telo-meric repeat-specific detection probe. The immobilized PCR products were detected with peroxidase-conjugated anti-DIG antibody. After addition of the stop reagent, the plate was assessed on a plate reader at a wavelength of 450 nm within 30 min. The cell extracts were heat inactivated for 10 min at 85°C and used as negative controls.
Statistical analysis
Statistical analysis was performed with GraphPad Prism5.0 (GraphPad Software, San Diego, CA, USA). The data are expressed as mean ± standard deviation (Fig. 1) .
Effect of BIBR1532 on cell viability
The telomerase inhibitor BIBR1532 has been demonstrated to inhibit telomerase activity in many human cancer cell lines resulting in progressive shortening and dysfunction of telomeres. We tested whether BIBR1532 treatment could decrease the viability of LN-18 cells, by using the MTT assay. LN18 cells were incubated with (or without) BIBR1532 at various concentrations ranging from 10 to 200 lM and the cell viability was monitored for 24, 48 and 72 h. LN18 cells showed a significant dose dependent cytotoxic effect with IC 50 value of 25 lM and 47, 56 and 62% reduction in cell viability after exposure to 25, 50 and 100 lM at 48 h. Treatment with 200 lM BIBR1532 caused more than 70% decrease in viability of LN18 cells at 48 and 72 h (Fig. 2) . Taken together, these findings suggest that increasing concentrations of BIBR1532 above the concentration of 25 lM could exert a direct growth suppressive and cytotoxic effect, in contrast to the long-term cell cycle arrest mediated by substantial telomere erosion.
The effect of BIBR1532 on a normal human cell line (CHME3) was performed to confirm selectivity. CHME3 cells showed a significant dose dependent cytotoxic effect with IC 50 value of 90 lM after 48 h. Cell viability was decreased to 56 and 49.6% after 24 and 48 h at a concentration of 90 lM (Supplementary Table 1 ).
Effect of BIBR1532 on hTERT expression in LN18 cells
To verify the inhibitory effects of BIBR1532 on telomerase activity, we examined whether this agent could modulate the expression levels of hTERT mRNA. Real time PCR results showed that the level of hTERT mRNA expression in cells treated with 25, 100 and 200 lM BIBR1532 treated groups was decreased * 21, * 61.2, and * 77%, respectively, with a p \ 0.05 (Fig. 3) . These results also demonstrated that hTERT mRNA levels were decreased in a dose-dependent manner.
Analysis of hTERT protein expression after treatment with various concentrations of BIBR1532 indicated significant down regulation of hTERT expression compared to untreated control. The level of hTERT protein was decreased to 44, 61, and 86%, at concentrations, of 25, 100, and 200 lM, respectively (Fig. 4) .
Effect of BIBR1532 on apoptosis in LN18 cells
To determine whether BIBR1532 induced apoptosis in LN18 cells Annexin V-FITC and PI staining was used to quantify apoptosis after treatment with BIBR1532 (Fig. 5) . The results showed a significant increase in the total percentage of apoptotic cells at 200 lM of BIBR1532 with 63.6, 73.8, and 84.5% total apoptotic cells at 12, 24, and 48 h, respectively, compared to control (Fig. 6 ). These data suggest that the growth inhibitory effect of BIBR 1532 on LN18 cells is through apoptosis.
Effect of BIBR1532 on telomerase activity
To determine whether inhibition of hTERT mRNA and protein was correlated with inhibition of telomerase activity, we tested the effect of BIBR1532 telomerase activity in LN18 cells. TRAP assay was performed using partially purified telomerase from cells treated with different concentrations of BIBR1532 for 48 h indicated dose-dependent manner inhibition. While 25 lM of BIBR1532 resulted in a 
Discussion
Telomerase plays an important role in cancer development. It regulates the length of telomeres in tumor cells, maintains proliferative capacity and tumor progression in 90% of human malignancies (Shay and Wright 2011) . hTERT, the catalytic component of telomerase is upregulated in several cancers including glioblastomas (Cong et al. 2002; Hahn et al. 1999 ). The expression and activity of telomerase was also correlated with poor survival in glioblastomas (Lotsch et al. 2013) . Thus, studying telomerase has enormous potential in diagnostic, prognostic, and therapeutic applications in various cancers.
Several methods have been developed to inhibit telomerase activity. Previous studies demonstrated that telomerase has been inhibited or inactivated via gene knockout, antisense oligonucleotides, peptide nucleic acids, or nucleosidic reverse target inhibitors (Hahn et al. 1999; Herbert et al. 1999; Strahl and Blackburn 1996) . But these methods showed limited success in vivo due to the inability of the compounds to cross cellular membranes under physiological conditions or due to their low efficacy. It has been reported that targeting either hTR or hTERT by antisense oligonucleotides reduced cell proliferation and tumor growth in human bladder and prostate cancer cells (Chen et al. 2003; Kraemer et al. 2004 ). However antisense strategies and gene therapy hold great potential for the treatment of several human diseases, but the possibility of gene therapy and clinical usefulness of most antisense compounds remain unclear. A previous study from our lab showed that, silencing of hTERT expression in glioblastoma cells by a specific siRNA resulted in decreased cell growth and increased cell apoptosis (Lavanya et al. 2016) . However, in the past, several challenges have been encountered in the delivery of siRNA into solid tumors. Therefore, the clinical application of hTERT siRNA in the treatment of glioblastoma cancer may require other confirmed apoptosis-inducing agents. Hence, the use of small molecule inhibitors, may be considered as a potential anti-telomerase therapy in patients with glioblastoma (Ward and Autexier 2005) .
Numerous telomerase inhibitors, that block either the activity of the telomerase or recruitment of the enzyme to telomeres, have been developed recently. One such compound is BIBR1532, which has opened the new therapeutic window of chemotherapy treatments. BIBR1532 is a non-nucleoside compound which binds to a site in the telomerase that is distinct from the site for deoxyribonucleotides and the DNA primer, and acts as a chain terminator during nucleotide polymerization, leading to inhibition of the catalytic activity of telomerase (Pascolo et al. 2002) . It has been demonstrated that BIBR1532 does not cause chain termination events but rather prevents the formation of long reaction products. In particular, BIBR1532 leads to an overall decrease in the number of added TTAGGG repeats. This suggests that the inhibitor not only block the basic catalytic steps involved in template copying but also specifically impairs the elongation of the DNA substrate after its extension to the 5 0 end of the template. Therefore, BIBR1532 may affect translocation of the enzyme DNA substrate complex or may promote dissociation between DNA substrate and the enzyme upon completion of template copying. As these steps are most likely unique to telomerase, this may project BIBR1532 a novel class of telomerase inhibitor (Pascolo et al. 2002) .
Telomerase inhibition using BIBR1532 in human cancer cells of different histological origin leads to progressive shortening of telomeres down to a critical checkpoint (Damm et al. 2001 ) and inhibition of cell proliferation and also reduction in the tumorigenic potential following xeno-transplantation into nude mice (De Cian et al. 2008 ). BIBR1532 could selectively inhibit telomerase and induce apoptosis in human cancer cell lines derived from lung, breast, fibrosarcoma and prostate carcinoma through p21-induced senescence (Damm et al. 2001; Shi et al. 2015) . In leukemia cells BIBR1532 directly induced a cytotoxic effect through the activation of p21 coupled with downregulation of c-Myc and hTERT transcription (Bashash et al. 2013 ). BIBR1532 inhibited the activity of telomerase through transcriptional suppression of survivin-mediated c-Myc and hTERT expression, increasing p73 and p21 expression, up-regulating the Bax/Bcl-2 molecular ratio and finally increasing P53-induced apoptosis (Bashash et al. 2012; Brassat et al. 2011) . TP53 is the final executant of the telomerase inhibiting effect of BIBR1532. In P53-negative K562 cells, the telomere length was stabilized when it reached approximately 5 kb (Brassat et al. 2011) .
Previous studies reported that long-term cultures of several human cancer cell lines in the presence of the telomerase inhibitor BIBR1532 at a concentration of 10 lM caused telomeric attrition and subsequent activation of the DNA damage response pathway, leading to cell cycle arrest and apoptosis (Damm et al. 2001) . It has been demonstrated that a dose-dependent growth suppressive and antiproliferative effect has been shown in leukemia cell lines using increasing concentrations of BIBR1532 above 20 lM (El-Daly et al. 2005) . Altogether, the results from previous studies demonstrated that BIBR1532 inhibits telomerase activity. In order to understand the role of BIBR1532 in altering telomerase activity, we first attempted to prove that BIBR1532 modulates telomerase activity and hTERT expression in glioblastoma cells.
In the current study, we have demonstrated that BIBR1532 represents a potent specific inhibitor of hTERT, which exhibits a selective cytotoxicity against the human glioblastoma cell LN18. This effect was observed when BIBR1532 was used at higher concentrations than at the previously reported concentration for inhibition of catalytic activity. This suggests that BIBR1532 exerts a direct cytotoxic potential, which may be separate from telomerase inhibition. The IC 50 value for the purified telomerase enzyme has been determined to be 93 nM. In contrast, concentrations higher than 100 lM were more effective to inhibit RNA polymerases I to III (Damm et al. 2001) .
We found that more than 70% decrease in viability when LN18 cells were exposed to the drug at a concentration of 200 lM of BIBR1532. Thus, an increase in the doses of BIBR1532 in cell culture results in a direct antiproliferative effect in contrast with delayed growth arrest. Evidence from previous studies showed that in endometrial cancer cells, inhibition of hTERT expression by BIBR1532 leads to an acute telomerase depletion and cell growth arrest (Kong et al. 2015) . We also observed that BIBR1532 showed more cytotoxic effect on LN18 cells at a lower concentration (IC 50 = 25 lM) when compared to CHME3 cells. These results suggest that LN18 cells are more sensitive to BIBR1532 at a low concentration than CHME3 cells.
Transcriptional regulation of hTERT and c-Myc is thought to be the major mechanism of human telomerase regulation (Cerni 2000; Wojtyla et al. 2011) . c-Myc is believed to be a strong regulator of telomerase, and its ability to induce the transcriptional activation of hTERT has been shown to be increased in survivin gene transfectant cells (Endoh et al. 2005) . To investigate the effect of BIBR1532 on transcription regulation of hTERT cells were subjected to treatment with different concentrations of BIBR1532. The mRNA and protein expression levels of hTERT were decreased in a dose-dependent manner following treatment with BIBR1532. Our data may define that high concentrations of BIBR1532 might delay cell proliferation and repress hTERT expression in LN18 cells through activation of c-Myc in glioblastoma cells. A previous study by Bashash et al. (2013) showed that decreased telomerase activity due to transcriptional suppression of survivin-mediated c-Myc and hTERT expression may be a postulated mechanism involved in BIBR1532-induced cell death in Nalm-6 leukemic cells (Bashash et al. 2013) .
We have observed that BIBR1532 exposure led to a dramatic suppression of telomerase activity in glioblastoma cells. In LN18 cells the significant inhibition of telomerase activity was observed at 48 h. Treatment with 25 lM of BIBR1532 resulted in a partial inhibition of telomerase activity in LN18 cells, whereas treatment with higher concentrations 100 and 200 lM was associated with significant telomerase inhibition. BIBR1532 treatment caused a dose-dependent decrease in transcription of hTERT and in telomerase activity. hTERT is tightly regulated by various transcription factors and the hTERT core promoter is known to have two c-Myc, five Sp1, one Ets, and two Inr binding sites (Cong et al. 1999; Horikawa et al. 1999) . In particular, the role of c-Myc in the regulation of hTERT transcription has been studied extensively (Kyo et al. 2000) . c-Myc has been shown to bind to the c-Myc recognition sequence (Ebox) at the promoter of hTERT and activate hTERT transcription (Wu et al. 1999) . Our results may support the fact that c-Myc controls the transcription of hTERT and also suggest that the repression of telomerase activity could be via the decreased c-Myc DNA binding activity.
Apoptosis or programmed cell death is usually characterized by distinct morphological characteristics and energy-dependent biochemical mechanisms (Elmore 2007) . The inhibition of telomerase activity has also been shown to induce apoptosis (Zhang et al. 2001 ). In our study, higher concentration BIBR1532 (200 lM) significantly resulted in an increase in apoptotic cells. However, BIBR1532 failed to catch early apoptosis response at all the time points.
Our results demonstrated that BIBR1532 induced apoptosis in human glioblastoma cells. This induction of apoptosis was associated with the down regulation of telomerase activity through transcriptional and posttranslational modification of hTERT. In view of accumulating evidence that BIBR1532 may be a therapeutic agent to suppress telomerase activity, further efforts are necessary in order to explore this therapeutic strategy.
